Drugs / BAY3389934
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07652723 | May → Dec 2026 expected | — | Bayer | Recruiting | No outcome recorded |
| Phase 1 | NCT07176728 | Sep 2025 → May 2026 | disseminated intravascular coagulation | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT06854640 | Mar 2025 → Dec 2026 expected | blood coagulation disease, infectious disease with sepsis | Bayer | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY3389934 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07652723 ↗ |
| Action | Inhibit | “By blocking them, BAY3389934 may slow down or stop excessive clotting.” NCT07652723 ↗ |
| Route | Intravenous | “Intravenous Infusion of BAY 3389934” NCT06854640 ↗ |